Novel treatment approaches are needed to overcome innate and acquired mechanisms of resistance to current anticancer therapies in cancer cells and the tumour immune microenvironment. The TAM (TYRO3, AXL and MERTK) family receptor tyrosine kinases (RTKs) are potential therapeutic targets in a wide range of cancers. In cancer cells, TAM RTKs activate signalling pathways that promote cell survival, metastasis and resistance to a variety of chemotherapeutic agents and targeted therapies. TAM RTKs also function in innate immune cells, contributing to various mechanisms that suppress antitumour immunity and promote resistance to immune-checkpoint inhibitors. Therefore, TAM antagonists provide an unprecedented opportunity for both direct and immune-mediated therapeutic activity provided by inhibition of a single target, and are likely to be particularly effective when used in combination with other cancer therapies. To exploit this potential, a variety of agents have been designed to selectively target TAM RTKs, many of which have now entered clinical testing. This Review provides an essential guide to the TAM RTKs for clinicians, including an overview of the rationale for therapeutic targeting of TAM RTKs in cancer cells and the tumour immune microenvironment, a description of the current preclinical and clinical experience with TAM inhibitors, and a perspective on strategies for continued development of TAM-targeted agents for oncology applications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41571-023-00813-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TYRO3 and EPHA2 Expression Are Dysregulated in Breast Cancer.
Cell Biochem Funct
September 2024
Keizo Asami Institute (iLIKA), Federal University of Pernambuco (UFPE), Recife, Pernambuco, Brazil.
Article Synopsis
- - Receptor tyrosine kinases (RTKs) play crucial roles in cell functions like growth and differentiation, and when their signaling is disrupted, it can lead to tumors and make treatments less effective.
- - This study analyzed gene expressions of specific RTKs (TAM, RON, EPHA2, and MET) in breast cancer tissues using qPCR, focusing on how these expressions relate to clinical data.
- - Findings suggest that the expression of TYRO3, MET, and EPHA2 is associated with factors like tumor subtype, patient age, and lifestyle choices such as smoking and obesity, indicating their potential significance in breast cancer.
Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain.
Elife
September 2024
Tetrad Graduate Program, University of California, San Francisco, San Francisco, United States.
MET is a receptor tyrosine kinase (RTK) responsible for initiating signaling pathways involved in development and wound repair. MET activation relies on ligand binding to the extracellular receptor, which prompts dimerization, intracellular phosphorylation, and recruitment of associated signaling proteins. Mutations, which are predominantly observed clinically in the intracellular juxtamembrane and kinase domains, can disrupt typical MET regulatory mechanisms.
View Article and Find Full Text PDFMERTK Inhibition as a Targeted Novel Cancer Therapy.
Int J Mol Sci
July 2024
Lineburger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
In this issue honoring the contributions of Greg Lemke, the Earp and Graham lab teams discuss several threads in the discovery, action, signaling, and translational/clinical potential of MERTK, originally called c-mer, a member of the TYRO3, AXL, and MERTK (TAM) family of receptor tyrosine kinases. The 30-year history of the TAM RTK family began slowly as all three members were orphan RTKs without known ligands and/or functions when discovered by three distinct alternate molecular cloning strategies in the pre-genome sequencing era. The pace of understanding their physiologic and pathophysiologic roles has accelerated over the last decade.
View Article and Find Full Text PDFTargeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition.
Cancers (Basel)
June 2024
Departments of Neurosurgery, Penn State University, Hershey, PA 17033, USA.
Triple-negative breast cancer (TNBC) is the most aggressive subtype with high metastasis and mortality rates. Given the lack of actionable targets such as ER and HER2, TNBC still remains an unmet therapeutic challenge. Despite harboring high CDK4/6 expression levels, the efficacy of CDK4/6 inhibition in TNBC has been limited due to the emergence of resistance.
View Article and Find Full Text PDFIn the Eyes of the Beholder-New Knockout Mouse and Re-Evaluation of Phagocytosis versus Anti-Inflammatory Functions of MERTK.
Int J Mol Sci
May 2024
Department of Pharmacology, School of Medicine, Yale University, New Haven, CT 06520, USA.
Greg Lemke's laboratory was one of the pioneers of research into the TAM family of receptor tyrosine kinases (RTKs). Not only was cloned in his laboratory, but his group also extensively studied mice knocked out for individual or various combinations of the TAM RTKs , , and . Here we primarily focus on one of the paralogs-MERTK.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!